17 results about "Methylenedioxy" patented technology

The present invention is directed to novel chemical compositions of matter, and in particular novel MDMA class of compounds having substituted methylenedioxyphenethylamine and substituted amphetamine, having a metabolically labile thioether group.

The application discloses a synthesis process of (-)-alpha-lycorane alkaloid and belongs to the technical field of organic synthesis chemistry. (2Z,4E)-7,7-diethoxy-3-hydroxyhepta-2,4-dienoic acid methyl ester and 3,4-methylenedioxy-beta-nitrostyrene are used as starting materials, and (-)-alpha-lycorane is obtained through catalytic asymmetric tandem Michael addition reaction, nitro reduction amination reaction, Boc amidation reaction, Bischler-Napieralski cyclization reaction, ketone enolization tandem esterification reaction, enol triflate reductive hydrogenolysis reaction and amide reduction reaction in sequence. (-)-Alpha-lycorane has a four-membered ring core skeleton of pyrrole-phenanthridine ring, has good in-vitro tumor inhibition activity and cell proliferation growth inhibition activity. The synthesis process can realize efficient, simple and full synthesis of (-)-alpha-lycorane.

This invention provides an ether-based electrolyte for improving the high-voltage and long-cycle stability of sodium-ion batteries, its preparation method, and its application. The ether-based electrolyte comprises a base electrolyte and additives; the additives include aromatic isocyanates and alkoxysilanes. The aromatic isocyanates are a combination of one of the following: 6-fluoro-1H-1,3-benzodioxane-8-yl isocyanate, 3,4-dihydro-1,5-benzodioxane-7-isocyanate, or 3,4-(methylenedioxy)phenyl isocyanate, and 4-trifluoromethoxyphenyl isocyanate; the alkoxysilanes are 2-cyanoethyltriethoxysilane or 3,3,3-trifluoropropyltriethoxysilane. The electrolyte of this invention achieves synergistic regulation of interfacial reactions and interfacial film evolution, is suitable for sodium-ion half-cells or full-cells, and can improve overall stability and operating efficiency under high-voltage and long-cycle operating conditions.

The application belongs to the field of biological medicine, and discloses a 2-methyl quinoline derivative with a structure as shown in formula I, R is selected from substituted phenyl as shown in the formula, n is an integer of 1-5, R1 is selected from C1-C3 alkyl, halogen-substituted C1-C3 alkyl, C1-C3 alkoxy, halogen-substituted C1-C3 alkoxy, 3,4-methylenedioxy, phenyl and -NR3R4; R3 and R4 are independently selected from H and C1-C3 alkyl; however, the substituted phenyl does not include p-methoxyphenyl and 3-amino-4-methoxyphenyl; X is selected from C and N, and R2 is selected from H and C1-C3 alkyl, but X cannot be selected from C and R2 cannot be selected from H at the same time. The 2-methyl quinoline derivative has good antitumor activity, and the toxicity to human normal cells is weaker than the toxicity to cancer cells. The application discloses application of the 2-methyl quinoline derivative in preparation of an antitumor drug.

The present application relates to the field of chemical pharmacy, and particularly relates to a preparation method of sertindole, comprising the following steps: taking 1-bromo-3,4-(methylenedioxy) benzene (compound A) and 4,4-dimethyl-1-penten-3-one (compound B) as raw materials, reacting the compound A with zinc powder to obtain an organic zinc reagent, and reacting the compound B with a chloro reagent to obtain a chloro compound with a terminal olefin substituted; then, the organic zinc reagent of the compound A and the chloro compound of the compound B are coupled to obtain an intermediate compound C; finally, the compound C is reduced to obtain sertindole.

The invention belongs to the technical field of organic synthesis and medicines, and particularly relates to an aminated 20 (S)-10, 11-difluoromethylenedioxy camptothecin derivative as well as a preparation method and application thereof. The derivative is a compound with a structure as shown in a formula (I), and in the formula (I), R is shown in the description; wherein X is an integer from 3 to 10, and n is an integer from 3 to 10; and Z is selected from (amido substitution). The novel aminated 20 (S)-10, 11-difluoromethylenedioxy camptothecin derivative provided by the invention has good in-vivo and in-vitro anti-tumor activity, and can be used for preparing and synthesizing camptothecin drugs for preventing or treating tumors, the preparation method is easy to operate, the post-treatment is simple and convenient, the initial raw materials of the reaction are cheap and easy to obtain, the designability of the reaction substrate is strong, and the method is suitable for industrial production. The reaction efficiency is relatively high, and the practicability is relatively high.

The present application relates to the technical field of biological analysis detection, and particularly relates to cucurbituril derivatives for drug detection, a preparation method and application of the cucurbituril derivatives, a detection probe containing the cucurbituril derivatives, a drug for treating drug acute poisoning, and a method for drug detection. The derivative introduces a functional group of o-cyanobenzaldehyde (CNBA) on the basis of retaining the original supramolecular recognition characteristics of cucurbituril, and the obtained compound can realize efficient covalent capture on the primary amine groups in common drugs and metabolites (such as methyl phenylpropylamine and its metabolites, 3,4-methylenedioxy methyl phenylpropylamine, ketamine and its metabolites, fluoroamine and its metabolites, phenylcyclohexylpiperidine, and casiketone molecules), so as to realize rapid, high-sensitivity and visual detection on the above target objects, and can be used for antagonistic treatment of acute poisoning caused by related drugs and metabolites.

In one aspect, the present disclosure provides a method of synthesis for methylone HCl, with 3,4-methylenedioxypropiophenone (MDP) as the starting material. In another aspect, the present disclosure provides stereoisomers of methylone. In another aspect, the present disclosure provides phenethylamines or cathinones covalently bound to a chemical moiety in a prodrug form. The presently described prodrug form allows slow / sustained / controlled delivery of the parent phenethylamines or cathinones into the blood system in a manner that would increase the duration of therapeutic efficacy.

The present invention is directed to chemical compositions of matter, and in particular a MDMA class of analogs having 1,3-benzothiazoles substituted at the 5 and 6-position with a basic or modified side chain.

The invention relates to medical uses of a compound of general formula (I), (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2, which can be the same group or a different group, are independently a hydroxy group or a methoxy group or, taken together, a methylenedioxy group, R3 and R4, which can be the same group or a different group, are independently a hydroxy group or a methoxy group, R5 is phenyl group, and R6 is a phenyl group, wherein said phenyl groups are independently optionally substituted, and wherein n is 2, and to pharmaceutical compositions comprising said compound of general formula (I), for use in the treatment of cancer in a human subject, wherein said compound of general formula (I) is administered in a therapeutically effective dose to said human subject. The invention is also related to medical uses of pharmaceutical compositions comprising said compound of general formula (I) or said pharmaceutically acceptable salt thereof.

The present invention includes a novel class of MDMA carbamates that can be activated in vivo as prodrugs. The MDMA prodrugs of the invention are enzymatically cleaved in vivo and produce alcohols of low toxicity that are well tolerated and metabolized in humans.

The present invention is directed to novel chemical compositions of matter, and in particular a novel MDMA class of compounds MDMA analogs having 1,3-benzothiazoles substituted at the 5 and 6-position with a MDMA basic or modified side chain.

The invention relates to a preparation method of N-hydroxyethyl-3, 4-methylenedioxy aniline, which comprises the following steps: (1) condensation reaction: taking pepper amine and ethylene carbonate as initial raw materials, and carrying out condensation reaction in a high-boiling-point ether solvent; (2) distillation: carrying out reduced pressure distillation on the reaction liquid obtained in the step (1) to recover the solvent so as to obtain an N-hydroxyethyl-3, 4-methylenedioxy aniline crude product; and (3) purification: carrying out post-treatment on the crude product of the N-hydroxyethyl-3, 4-methylenedioxy aniline to obtain a refined product of the N-hydroxyethyl-3, 4-methylenedioxy aniline. The method reduces environmental pollution while improving the product quality, and has the characteristics of greenness, low cost, simplicity in operation and the like; according to the invention, the production of the product is clean, safe and environment-friendly, so that the product is more suitable for mass production.

The application discloses a use of an aporphine alkaloid shown in formula III in preparation of an antidepressant, wherein R1 and R2 are independently selected from alkoxy and methylenedioxy, R3 and R4 are independently selected from H, OH, alkoxy and methylenedioxy, but R3 and R4 cannot be H at the same time or R1 and R2 are both selected from methoxy, and R3 cannot be OH and R4 cannot be H. Pharmacological experiments show that the aporphine alkaloid shown in formula III has better antidepressant effect, higher response rate and faster effect than fluoxetine.

The invention belongs to the field of organic chemistry, and particularly relates to a synthetic method of berberine hydrochloride. The method comprises the following steps: taking 3, 4-dimethoxyphenylethylamine hydrochloride and 3, 4-methylenedioxybenzaldehyde as starting raw materials, carrying out three-step reaction in sequence, sequentially carrying out oxidative cyclization, selective reduction and quaternization ring closing, and finally directly obtaining the target product berberine hydrochloride through acid treatment. The technical scheme has the characteristics of high efficiency, simplicity and high industrial cost performance in synthesis of berberine hydrochloride, the whole reaction is green and safe, the reaction conditions are mild, the reaction process has extremely high selectivity, and a berberine hydrochloride product with higher purity can be obtained.

The application provides a 7-position and 20-position substituted camptothecin derivative and application thereof, and belongs to the technical field of medicines. The 7-position and 20-position substituted camptothecin derivative provided by the application, or a stereoisomer and a pharmaceutically acceptable salt thereof has a structure shown in formula (I) or formula (II). By introducing a methylenedioxy group at 10, 11-positions and introducing different substituent groups at 7-positions or 20-positions through 1, 2, 3-triazole on the basis of a traditional camptothecin structure, a camptothecin derivative with excellent antitumor activity can be obtained. The obtained 7-position and 20-position substituted camptothecin derivative has clear structural characteristics, is convenient to synthesize, and is simple, fast and convenient to purify, and can be used for preparing a medicine for preventing or treating cancer, and has a wide application prospect.